Triple Negative Breast Cancer

Why trials studying Triple Negative Breast Cancer stopped, in this sample of ClinicalTrials.gov.

21 stopped trials with a clear reason; 71% ended for non-scientific reasons.

Trials

• TNBC Gut Microbiota During Neoadjuvant Treatment
  NCT06610097 · WITHDRAWN · slow accrual
  “no patients were able to be enrolled”
• Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)
  NCT06246786 · WITHDRAWN · slow accrual
  “Unable to enroll to study.”
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
  NCT06052852 · TERMINATED · funding business
  “Sponsor decision”
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
  NCT05714553 · TERMINATED · funding business
  “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”
• Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer
  NCT04268693 · WITHDRAWN · logistics pi
  “Study never initiated due to COVID pandemic, staffing changes”
• Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
  NCT05300958 · TERMINATED · slow accrual
  “Difficulty accruing subjects the study accrual was closed.”
• A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
  NCT05234606 · WITHDRAWN · funding business
  “Sponsor decision based on strategic re-alignment”
• Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
  NCT05233696 · WITHDRAWN · slow accrual
  “Low Accrual”
• Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
  NCT05113966 · TERMINATED · logistics pi
  “The Sponsor decided to close enrollment to the study on Feb 14, 2023, in order to reallocate resources to other ongoing trilaciclib clinical trials.”
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
  NCT04725331 · TERMINATED · funding business
  “Sponsor decision following completion of Phase I part not driven by safety reason”
• A Study of PY314 in Subjects With Advanced Solid Tumors
  NCT04691375 · TERMINATED · funding business
  “Sponsor business decision.”
• Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
  NCT03982173 · WITHDRAWN · other
  “Similar clinical trials showed not very encouraging results, which made us decide, after several modifications to the protocol and numerous difficulties encountered, to abandon the trial.”
• A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
  NCT04442126 · TERMINATED · funding business
  “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”
• A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
  NCT04025216 · TERMINATED · safety
  “The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.”
• A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
  NCT03901469 · TERMINATED · futility
  “Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued based on results from an interim futility analysis and not due to safety concerns.”
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
  NCT04234113 · TERMINATED · futility
  “Due to lack of efficacy shown at the time of the interim analysis.”
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
  NCT03829501 · TERMINATED · funding business
  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”
• REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
  NCT03435640 · TERMINATED · funding business
  “Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.”
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
  NCT03184558 · TERMINATED · futility
  “Based on planned futility assessment”
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
  NCT02576665 · TERMINATED · funding business
  “Sponsor decision”
• Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
  NCT02368691 · TERMINATED · futility
  “Lack of Efficacy”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.